Skip to main content
Erschienen in: Die Kardiologie 2/2022

25.02.2022 | Chronische Nierenerkrankung | Schwerpunkt Zur Zeit gratis

Irreversible posttranslationale Modifikationen: potenzielle kardiovaskuläre Risikofaktoren

Ergebnisse & Erkenntnisse aus dem SFB/TRR219 „Molekulare Mechanismen kardiovaskulärer Erkrankungen bei chronischer Niereninsuffizienz“

verfasst von: Prof. Dr. Joachim Jankowski, Prof. Dr. Danilo Fliser

Erschienen in: Die Kardiologie | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Trotz einer breiten Palette von Arzneimitteln zur Primärprävention von Herz-Kreislauf-Erkrankungen, wie z. B. Lipidsenker, Blutdrucksenker und Antidiabetika, sind diese nach wie vor die häufigste Todesursache weltweit. Dies wirft die Frage auf nach neuen/weiteren Risikofaktoren neben den bekannten traditionellen wie Hypercholesterinämie, Hypertonie und Diabetes mellitus. Mit der kontinuierlichen massenspektrometrischen Identifizierung und funktionelle Charakterisierung nichtenzymatischer posttranslational modifizierter Isoformen von Proteinen und Lipoproteinen wird immer deutlicher, dass irreversible nichtenzymatische posttranslationale Modifikationen (PTM) die biologischen Funktionen nativer Proteine und Lipoproteine verändern und sie in potenzielle kardiovaskuläre Risikofaktoren verwandeln. Insbesondere eine chronische Niereninsuffizienz führt zur systemisch erhöhten Konzentration reaktiver Metabolite und damit zu einer vermehrten Bildung nichtenzymatischer posttranslationaler Modifikationen, was die Entwicklung urämischer Komplikationen, v. a. von Herz-Kreislauf-Erkrankungen fördert. Nichtenzymatische PTM sind nicht nur bei urämischen Patienten an der Genese und Progression von Herz-Kreislauf-Erkrankungen beteiligt und stellen einen bedeutenden und neuartigen kardiovaskulären Risikomarker dar. Diese Erkenntnisse eröffnen potenziell neue Wege für Risikobewertung, Prävention und Therapie der betreffenden Patienten.
Literatur
1.
Zurück zum Zitat Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos EA, Maggioni AP, Kazakiewicz D, May HT, De Smedt D, Flather M, Zuhlke L, Beltrame JF, Huculeci R, Tavazzi L, Hindricks G, Bax J, Casadei B, Achenbach S, Wright L, Vardas P, European Society of C (2020) European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J 41:12–85PubMed Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos EA, Maggioni AP, Kazakiewicz D, May HT, De Smedt D, Flather M, Zuhlke L, Beltrame JF, Huculeci R, Tavazzi L, Hindricks G, Bax J, Casadei B, Achenbach S, Wright L, Vardas P, European Society of C (2020) European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J 41:12–85PubMed
2.
Zurück zum Zitat Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW (2020) American Heart Association Council on E, Prevention Statistics C and Stroke Statistics S. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation 141:e139–e596PubMed Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW (2020) American Heart Association Council on E, Prevention Statistics C and Stroke Statistics S. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation 141:e139–e596PubMed
3.
Zurück zum Zitat Speer T, Owala FO, Holy EW, Zewinger S, Frenzel FL, Stahli BE, Razavi M, Triem S, Cvija H, Rohrer L, Seiler S, Heine GH, Jankowski V, Jankowski J, Camici GG, Akhmedov A, Fliser D, Luscher TF, Tanner FC (2014) Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur Heart J 35:3021–3032PubMed Speer T, Owala FO, Holy EW, Zewinger S, Frenzel FL, Stahli BE, Razavi M, Triem S, Cvija H, Rohrer L, Seiler S, Heine GH, Jankowski V, Jankowski J, Camici GG, Akhmedov A, Fliser D, Luscher TF, Tanner FC (2014) Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur Heart J 35:3021–3032PubMed
4.
Zurück zum Zitat Sun JT, Yang K, Lu L, Zhu ZB, Zhu JZ, Ni JW, Han H, Chen N, Zhang RY (2016) Increased carbamylation level of HDL in end-stage renal disease: carbamylated-HDL attenuated endothelial cell function. Am J Physiol Renal Physiol 310:F511–F517PubMed Sun JT, Yang K, Lu L, Zhu ZB, Zhu JZ, Ni JW, Han H, Chen N, Zhang RY (2016) Increased carbamylation level of HDL in end-stage renal disease: carbamylated-HDL attenuated endothelial cell function. Am J Physiol Renal Physiol 310:F511–F517PubMed
5.
Zurück zum Zitat Rubenstein DA, Maria Z, Yin W (2011) Glycated albumin modulates endothelial cell thrombogenic and inflammatory responses. J Diabetes Sci Technol 5:703–713PubMedPubMedCentral Rubenstein DA, Maria Z, Yin W (2011) Glycated albumin modulates endothelial cell thrombogenic and inflammatory responses. J Diabetes Sci Technol 5:703–713PubMedPubMedCentral
6.
Zurück zum Zitat Thanopoulou A, Karamanos B, Archimandritis A (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362:2030–2031 (author reply 2031)PubMed Thanopoulou A, Karamanos B, Archimandritis A (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362:2030–2031 (author reply 2031)PubMed
8.
Zurück zum Zitat Harmel R, Fiedler D (2018) Features and regulation of non-enzymatic post-translational modifications. Nat Chem Biol 14:244–252PubMed Harmel R, Fiedler D (2018) Features and regulation of non-enzymatic post-translational modifications. Nat Chem Biol 14:244–252PubMed
9.
Zurück zum Zitat Santos AL, Lindner AB (2017) Protein posttranslational modifications: roles in aging and age-related disease. Oxid Med Cell Longev 2017:5716409PubMedPubMedCentral Santos AL, Lindner AB (2017) Protein posttranslational modifications: roles in aging and age-related disease. Oxid Med Cell Longev 2017:5716409PubMedPubMedCentral
10.
Zurück zum Zitat Singh VP, Bali A, Singh N, Jaggi AS (2014) Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 18:1–14PubMedPubMedCentral Singh VP, Bali A, Singh N, Jaggi AS (2014) Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 18:1–14PubMedPubMedCentral
11.
Zurück zum Zitat Gajjala PR, Fliser D, Speer T, Jankowski V, Jankowski J (2015) Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease. Nephrol Dial Transplant 30:1814–1824PubMed Gajjala PR, Fliser D, Speer T, Jankowski V, Jankowski J (2015) Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease. Nephrol Dial Transplant 30:1814–1824PubMed
12.
Zurück zum Zitat Irving RM, Elfarra AA (2012) Role of reactive metabolites in the circulation in extrahepatic toxicity. Expert Opin Drug Metab Toxicol 8:1157–1172PubMedPubMedCentral Irving RM, Elfarra AA (2012) Role of reactive metabolites in the circulation in extrahepatic toxicity. Expert Opin Drug Metab Toxicol 8:1157–1172PubMedPubMedCentral
13.
Zurück zum Zitat Okoduwa SI, Umar IA, Ibrahim S, Bello F, Habila N (2015) Age-dependent alteration of antioxidant defense system in hypertensive and type‑2 diabetes patients. J Diabetes Metab Disord 14:32PubMedPubMedCentral Okoduwa SI, Umar IA, Ibrahim S, Bello F, Habila N (2015) Age-dependent alteration of antioxidant defense system in hypertensive and type‑2 diabetes patients. J Diabetes Metab Disord 14:32PubMedPubMedCentral
14.
Zurück zum Zitat Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL (2007) Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 13:1176–1184PubMed Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL (2007) Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 13:1176–1184PubMed
15.
Zurück zum Zitat Zoltowska M, Delvin E, Ziv E, Peretti N, Chartre M, Levy E (2004) Impact of in vivo glycation of LDL on platelet aggregation and monocyte chemotaxis in diabetic psammomys obesus. Lipids 39:81–85PubMed Zoltowska M, Delvin E, Ziv E, Peretti N, Chartre M, Levy E (2004) Impact of in vivo glycation of LDL on platelet aggregation and monocyte chemotaxis in diabetic psammomys obesus. Lipids 39:81–85PubMed
16.
Zurück zum Zitat Kashyap SR, Osme A, Ilchenko S, Golizeh M, Lee K, Wang S, Bena J, Previs SF, Smith JD, Kasumov T (2018) Glycation reduces the stability of ApoAI and increases HDL dysfunction in diet-controlled type 2 diabetes. J Clin Endocrinol Metab 103:388–396PubMed Kashyap SR, Osme A, Ilchenko S, Golizeh M, Lee K, Wang S, Bena J, Previs SF, Smith JD, Kasumov T (2018) Glycation reduces the stability of ApoAI and increases HDL dysfunction in diet-controlled type 2 diabetes. J Clin Endocrinol Metab 103:388–396PubMed
17.
Zurück zum Zitat Kameda K, Matsunaga T, Abe N, Hanada H, Ishizaka H, Ono H, Saitoh M, Fukui K, Fukuda I, Osanai T, Okumura K (2003) Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J 24:2180–2185PubMed Kameda K, Matsunaga T, Abe N, Hanada H, Ishizaka H, Ono H, Saitoh M, Fukui K, Fukuda I, Osanai T, Okumura K (2003) Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J 24:2180–2185PubMed
18.
Zurück zum Zitat Du Q, Qian MM, Liu PL, Zhang L, Wang Y, Liu DH (2017) Glycation of high-density lipoprotein triggers oxidative stress and promotes the proliferation and migration of vascular smooth muscle cells. J Geriatr Cardiol 14:473–480PubMedPubMedCentral Du Q, Qian MM, Liu PL, Zhang L, Wang Y, Liu DH (2017) Glycation of high-density lipoprotein triggers oxidative stress and promotes the proliferation and migration of vascular smooth muscle cells. J Geriatr Cardiol 14:473–480PubMedPubMedCentral
19.
Zurück zum Zitat Le QH, El Alaoui M, Vericel E, Segrestin B, Soulere L, Guichardant M, Lagarde M, Moulin P, Calzada C (2015) Glycoxidized HDL, HDL enriched with oxidized phospholipids and HDL from diabetic patients inhibit platelet function. J Clin Endocrinol Metab 100:2006–2014PubMed Le QH, El Alaoui M, Vericel E, Segrestin B, Soulere L, Guichardant M, Lagarde M, Moulin P, Calzada C (2015) Glycoxidized HDL, HDL enriched with oxidized phospholipids and HDL from diabetic patients inhibit platelet function. J Clin Endocrinol Metab 100:2006–2014PubMed
20.
Zurück zum Zitat Misciagna G, Logroscino G, De Michele G, Guerra V, Cisternino AM, Caruso MG, Trevisan M (2007) Glycated apolipoprotein B and myocardial infarction. Nutr Metab Cardiovasc Dis 17:6–12PubMed Misciagna G, Logroscino G, De Michele G, Guerra V, Cisternino AM, Caruso MG, Trevisan M (2007) Glycated apolipoprotein B and myocardial infarction. Nutr Metab Cardiovasc Dis 17:6–12PubMed
21.
Zurück zum Zitat Holzer M, Gauster M, Pfeifer T, Wadsack C, Fauler G, Stiegler P, Koefeler H, Beubler E, Schuligoi R, Heinemann A, Marsche G (2011) Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid Redox Signal 14:2337–2346PubMed Holzer M, Gauster M, Pfeifer T, Wadsack C, Fauler G, Stiegler P, Koefeler H, Beubler E, Schuligoi R, Heinemann A, Marsche G (2011) Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid Redox Signal 14:2337–2346PubMed
22.
Zurück zum Zitat Rueth M, Lemke HD, Preisinger C, Krieter D, Theelen W, Gajjala P, Devine E, Zidek W, Jankowski J, Jankowski V (2015) Guanidinylations of albumin decreased binding capacity of hydrophobic metabolites. Acta Physiol 215:13–23 Rueth M, Lemke HD, Preisinger C, Krieter D, Theelen W, Gajjala P, Devine E, Zidek W, Jankowski J, Jankowski V (2015) Guanidinylations of albumin decreased binding capacity of hydrophobic metabolites. Acta Physiol 215:13–23
23.
Zurück zum Zitat Schuett K, Savvaidis A, Maxeiner S, Lysaja K, Jankowski V, Schirmer SH, Dimkovic N, Boor P, Kaesler N, Dekker FW, Floege J, Marx N, Schlieper G (2017) Clot structure: a potent mortality risk factor in patients on hemodialysis. J Am Soc Nephrol 28:1622–1630PubMedPubMedCentral Schuett K, Savvaidis A, Maxeiner S, Lysaja K, Jankowski V, Schirmer SH, Dimkovic N, Boor P, Kaesler N, Dekker FW, Floege J, Marx N, Schlieper G (2017) Clot structure: a potent mortality risk factor in patients on hemodialysis. J Am Soc Nephrol 28:1622–1630PubMedPubMedCentral
24.
Zurück zum Zitat Binder V, Bergum B, Jaisson S, Gillery P, Scavenius C, Spriet E, Nyhaug AK, Roberts HM, Chapple ILC, Hellvard A, Delaleu N, Mydel P (2017) Impact of fibrinogen carbamylation on fibrin clot formation and stability. Thromb Haemost 117:899–910PubMedPubMedCentral Binder V, Bergum B, Jaisson S, Gillery P, Scavenius C, Spriet E, Nyhaug AK, Roberts HM, Chapple ILC, Hellvard A, Delaleu N, Mydel P (2017) Impact of fibrinogen carbamylation on fibrin clot formation and stability. Thromb Haemost 117:899–910PubMedPubMedCentral
27.
Zurück zum Zitat Zewinger S, Reiser J, Jankowski V, Alansary D, Hahm E, Triem S, Klug M, Schunk SJ, Schmit D, Kramann R, Korbel C, Ampofo E, Laschke MW, Selejan SR, Paschen A, Herter T, Schuster S, Silbernagel G, Sester M, Sester U, Assmann G, Bals R, Kostner G, Jahnen-Dechent W, Menger MD, Rohrer L, Marz W, Bohm M, Jankowski J, Kopf M, Latz E, Niemeyer BA, Fliser D, Laufs U, Speer T (2020) Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat Immunol 21:30–41PubMed Zewinger S, Reiser J, Jankowski V, Alansary D, Hahm E, Triem S, Klug M, Schunk SJ, Schmit D, Kramann R, Korbel C, Ampofo E, Laschke MW, Selejan SR, Paschen A, Herter T, Schuster S, Silbernagel G, Sester M, Sester U, Assmann G, Bals R, Kostner G, Jahnen-Dechent W, Menger MD, Rohrer L, Marz W, Bohm M, Jankowski J, Kopf M, Latz E, Niemeyer BA, Fliser D, Laufs U, Speer T (2020) Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat Immunol 21:30–41PubMed
28.
Zurück zum Zitat Berger S, Raman G, Vishwanathan R, Jacques PF, Johnson EJ (2015) Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr 102:276–294PubMed Berger S, Raman G, Vishwanathan R, Jacques PF, Johnson EJ (2015) Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr 102:276–294PubMed
29.
Zurück zum Zitat Apostolov EO, Ray D, Savenka AV, Shah SV, Basnakian AG (2010) Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol 21:1852–1857PubMedPubMedCentral Apostolov EO, Ray D, Savenka AV, Shah SV, Basnakian AG (2010) Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol 21:1852–1857PubMedPubMedCentral
30.
Zurück zum Zitat Artwohl M, Graier WF, Roden M, Bischof M, Freudenthaler A, Waldhausl W, Baumgartner-Parzer SM (2003) Diabetic LDL triggers apoptosis in vascular endothelial cells. Diabetes 52:1240–1247PubMed Artwohl M, Graier WF, Roden M, Bischof M, Freudenthaler A, Waldhausl W, Baumgartner-Parzer SM (2003) Diabetic LDL triggers apoptosis in vascular endothelial cells. Diabetes 52:1240–1247PubMed
31.
Zurück zum Zitat Navab M, Reddy ST, Van Lenten BJ, Fogelman AM (2011) HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8:222–232PubMed Navab M, Reddy ST, Van Lenten BJ, Fogelman AM (2011) HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8:222–232PubMed
32.
Zurück zum Zitat Jaisson S, Kerkeni M, Santos-Weiss IC, Addad F, Hammami M, Gillery P (2015) Increased serum homocitrulline concentrations are associated with the severity of coronary artery disease. Clin Chem Lab Med 53:103–110PubMed Jaisson S, Kerkeni M, Santos-Weiss IC, Addad F, Hammami M, Gillery P (2015) Increased serum homocitrulline concentrations are associated with the severity of coronary artery disease. Clin Chem Lab Med 53:103–110PubMed
33.
Zurück zum Zitat Pan B, Ren H, Ma Y, Liu D, Yu B, Ji L, Pan L, Li J, Yang L, Lv X, Shen X, Chen B, Zhang Y, Willard B, He Y, Zheng L (2012) High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells. Int J Cancer 131:70–82PubMed Pan B, Ren H, Ma Y, Liu D, Yu B, Ji L, Pan L, Li J, Yang L, Lv X, Shen X, Chen B, Zhang Y, Willard B, He Y, Zheng L (2012) High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells. Int J Cancer 131:70–82PubMed
34.
Zurück zum Zitat Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, Rye KA (2007) The impact of glycation on apolipoprotein A‑I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 50:643–653PubMed Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, Rye KA (2007) The impact of glycation on apolipoprotein A‑I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 50:643–653PubMed
35.
Zurück zum Zitat Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM (2016) A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol 10:472–489PubMed Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM (2016) A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol 10:472–489PubMed
36.
Zurück zum Zitat Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Pravastatin or atorvastatin E and infection therapy-thrombolysis in myocardial infarction I. intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504PubMed Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Pravastatin or atorvastatin E and infection therapy-thrombolysis in myocardial infarction I. intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504PubMed
37.
Zurück zum Zitat LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets I (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435PubMed LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets I (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435PubMed
38.
Zurück zum Zitat Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, Incremental Decrease in End Points Through Aggressive Lipid Lowering Study G (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437–2445PubMed Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, Incremental Decrease in End Points Through Aggressive Lipid Lowering Study G (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437–2445PubMed
39.
Zurück zum Zitat Fernandez-Friera L, Fuster V, Lopez-Melgar B, Oliva B, Garcia-Ruiz JM, Mendiguren J, Bueno H, Pocock S, Ibanez B, Fernandez-Ortiz A, Sanz J (2017) Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors. J Am Coll Cardiol 70:2979–2991PubMed Fernandez-Friera L, Fuster V, Lopez-Melgar B, Oliva B, Garcia-Ruiz JM, Mendiguren J, Bueno H, Pocock S, Ibanez B, Fernandez-Ortiz A, Sanz J (2017) Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors. J Am Coll Cardiol 70:2979–2991PubMed
40.
Zurück zum Zitat Pirillo A, Norata GD, Catapano AL (2013) LOX‑1, OxLDL, and atherosclerosis. Mediators Inflamm 2013:152786PubMedPubMedCentral Pirillo A, Norata GD, Catapano AL (2013) LOX‑1, OxLDL, and atherosclerosis. Mediators Inflamm 2013:152786PubMedPubMedCentral
41.
Zurück zum Zitat Bose C, Shah SV, Karaduta OK, Kaushal GP (2016) Carbamylated low-density lipoprotein (cLDL)-mediated induction of autophagy and its role in endothelial cell injury. PLoS ONE 11:e165576PubMedPubMedCentral Bose C, Shah SV, Karaduta OK, Kaushal GP (2016) Carbamylated low-density lipoprotein (cLDL)-mediated induction of autophagy and its role in endothelial cell injury. PLoS ONE 11:e165576PubMedPubMedCentral
42.
Zurück zum Zitat Ok E, Basnakian AG, Apostolov EO, Barri YM, Shah SV (2005) Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int 68:173–178PubMed Ok E, Basnakian AG, Apostolov EO, Barri YM, Shah SV (2005) Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int 68:173–178PubMed
43.
Zurück zum Zitat Apostolov EO, Shah SV, Ok E, Basnakian AG (2007) Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule‑1 and vascular cell adhesion molecule‑1. Arterioscler Thromb Vasc Biol 27:826–832PubMed Apostolov EO, Shah SV, Ok E, Basnakian AG (2007) Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule‑1 and vascular cell adhesion molecule‑1. Arterioscler Thromb Vasc Biol 27:826–832PubMed
44.
Zurück zum Zitat Siddiqui K, George TP, Nawaz SS, Yaslam M, Almogbel E, Al-Rubeaan K (2019) Significance of glycated LDL in different stages of diabetic nephropathy. Diabetes Metab Syndr 13:548–552PubMed Siddiqui K, George TP, Nawaz SS, Yaslam M, Almogbel E, Al-Rubeaan K (2019) Significance of glycated LDL in different stages of diabetic nephropathy. Diabetes Metab Syndr 13:548–552PubMed
45.
Zurück zum Zitat Sobenin IA, Tertov VV, Orekhov AN, Smirnov VN (1991) Synergetic effect of desialylated and glycated low density lipoproteins on cholesterol accumulation in cultured smooth muscle intimal cells. Atherosclerosis 89:151–154PubMed Sobenin IA, Tertov VV, Orekhov AN, Smirnov VN (1991) Synergetic effect of desialylated and glycated low density lipoproteins on cholesterol accumulation in cultured smooth muscle intimal cells. Atherosclerosis 89:151–154PubMed
46.
Zurück zum Zitat Rabbani N, Godfrey L, Xue M, Shaheen F, Geoffrion M, Milne R, Thornalley PJ (2011) Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes 60:1973–1980PubMedPubMedCentral Rabbani N, Godfrey L, Xue M, Shaheen F, Geoffrion M, Milne R, Thornalley PJ (2011) Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes 60:1973–1980PubMedPubMedCentral
47.
Zurück zum Zitat Ferretti G, Rabini RA, Bacchetti T, Vignini A, Salvolini E, Ravaglia F, Curatola G, Mazzanti L (2002) Glycated low density lipoproteins modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab 87:2180–2184PubMed Ferretti G, Rabini RA, Bacchetti T, Vignini A, Salvolini E, Ravaglia F, Curatola G, Mazzanti L (2002) Glycated low density lipoproteins modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab 87:2180–2184PubMed
48.
Zurück zum Zitat De Michele G, Correale M, De Michele O, Guerra V, Mazzarelli R, Misciagna G (2008) Evaluation of serum biomarkers in nutritional disorders: glycated apolipoprotein B, fasting serum glucose, fructosamine, stable and labile glycated hemoglobin in diabetic and non-diabetic subjects. Immunopharmacol Immunotoxicol 30:925–936PubMed De Michele G, Correale M, De Michele O, Guerra V, Mazzarelli R, Misciagna G (2008) Evaluation of serum biomarkers in nutritional disorders: glycated apolipoprotein B, fasting serum glucose, fructosamine, stable and labile glycated hemoglobin in diabetic and non-diabetic subjects. Immunopharmacol Immunotoxicol 30:925–936PubMed
49.
Zurück zum Zitat Kahlon AS, Pathak R (2011) Patterns of glycemic control using glycosylated hemoglobin in diabetics. J Pharm Bioallied Sci 3:324–328PubMedPubMedCentral Kahlon AS, Pathak R (2011) Patterns of glycemic control using glycosylated hemoglobin in diabetics. J Pharm Bioallied Sci 3:324–328PubMedPubMedCentral
50.
Zurück zum Zitat Berg AH, Drechsler C, Wenger J, Buccafusca R, Hod T, Kalim S, Ramma W, Parikh SM, Steen H, Friedman DJ, Danziger J, Wanner C, Thadhani R, Karumanchi SA (2013) Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med 5:175ra29PubMedPubMedCentral Berg AH, Drechsler C, Wenger J, Buccafusca R, Hod T, Kalim S, Ramma W, Parikh SM, Steen H, Friedman DJ, Danziger J, Wanner C, Thadhani R, Karumanchi SA (2013) Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med 5:175ra29PubMedPubMedCentral
51.
Zurück zum Zitat Bourdon E, Loreau N, Blache D (1999) Glucose and free radicals impair the antioxidant properties of serum albumin. Faseb J 13:233–244PubMed Bourdon E, Loreau N, Blache D (1999) Glucose and free radicals impair the antioxidant properties of serum albumin. Faseb J 13:233–244PubMed
52.
Zurück zum Zitat Joorgensen KA, Stoffersen E (1979) Heparin like activity of albumin. Thromb Res 16:569–574PubMed Joorgensen KA, Stoffersen E (1979) Heparin like activity of albumin. Thromb Res 16:569–574PubMed
53.
Zurück zum Zitat Sankaranarayanan S, de la Llera-Moya M, Drazul-Schrader D, Phillips MC, Kellner-Weibel G, Rothblat GH (2013) Serum albumin acts as a shuttle to enhance cholesterol efflux from cells. J Lipid Res 54:671–676PubMedPubMedCentral Sankaranarayanan S, de la Llera-Moya M, Drazul-Schrader D, Phillips MC, Kellner-Weibel G, Rothblat GH (2013) Serum albumin acts as a shuttle to enhance cholesterol efflux from cells. J Lipid Res 54:671–676PubMedPubMedCentral
54.
Zurück zum Zitat Cohen MP, Shea E, Chen S, Shearman CW (2003) Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. J Lab Clin Med 141:242–249PubMed Cohen MP, Shea E, Chen S, Shearman CW (2003) Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. J Lab Clin Med 141:242–249PubMed
55.
Zurück zum Zitat Dengler TJ, Robertz-Vaupel GM, Dengler HJ (1992) Albumin binding in uraemia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin. Eur J Clin Pharmacol 43:491–499PubMed Dengler TJ, Robertz-Vaupel GM, Dengler HJ (1992) Albumin binding in uraemia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin. Eur J Clin Pharmacol 43:491–499PubMed
56.
Zurück zum Zitat Blankenberg S, Barbaux S, Tiret L (2003) Adhesion molecules and atherosclerosis. Atherosclerosis 170:191–203PubMed Blankenberg S, Barbaux S, Tiret L (2003) Adhesion molecules and atherosclerosis. Atherosclerosis 170:191–203PubMed
57.
Zurück zum Zitat Liu SX, Hou FF, Guo ZJ, Nagai R, Zhang WR, Liu ZQ, Zhou ZM, Zhou M, Xie D, Wang GB, Zhang X (2006) Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26:1156–1162PubMed Liu SX, Hou FF, Guo ZJ, Nagai R, Zhang WR, Liu ZQ, Zhou ZM, Zhou M, Xie D, Wang GB, Zhang X (2006) Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26:1156–1162PubMed
58.
Zurück zum Zitat Rubenstein DA, Yin W (2009) Glycated albumin modulates platelet susceptibility to flow induced activation and aggregation. Platelets 20:206–215PubMed Rubenstein DA, Yin W (2009) Glycated albumin modulates platelet susceptibility to flow induced activation and aggregation. Platelets 20:206–215PubMed
59.
60.
Zurück zum Zitat Chong-Martinez B, Buchanan TA, Wenby RB, Meiselman HJ (2003) Decreased red blood cell aggregation subsequent to improved glycaemic control in Type 2 diabetes mellitus. Diabet Med 20:301–306PubMed Chong-Martinez B, Buchanan TA, Wenby RB, Meiselman HJ (2003) Decreased red blood cell aggregation subsequent to improved glycaemic control in Type 2 diabetes mellitus. Diabet Med 20:301–306PubMed
61.
Zurück zum Zitat Pietrement C, Gorisse L, Jaisson S, Gillery P (2013) Chronic increase of urea leads to carbamylated proteins accumulation in tissues in a mouse model of CKD. Plos One 8:e82506PubMedPubMedCentral Pietrement C, Gorisse L, Jaisson S, Gillery P (2013) Chronic increase of urea leads to carbamylated proteins accumulation in tissues in a mouse model of CKD. Plos One 8:e82506PubMedPubMedCentral
62.
Zurück zum Zitat Jaisson S, Lorimier S, Ricard-Blum S, Sockalingum GD, Delevallee-Forte C, Kegelaer G, Manfait M, Garnotel R, Gillery P (2006) Impact of carbamylation on type I collagen conformational structure and its ability to activate human polymorphonuclear neutrophils. Chem Biol 13:149–159PubMed Jaisson S, Lorimier S, Ricard-Blum S, Sockalingum GD, Delevallee-Forte C, Kegelaer G, Manfait M, Garnotel R, Gillery P (2006) Impact of carbamylation on type I collagen conformational structure and its ability to activate human polymorphonuclear neutrophils. Chem Biol 13:149–159PubMed
63.
Zurück zum Zitat Garnotel R, Sabbah N, Jaisson S, Gillery P (2004) Enhanced activation of and increased production of matrix metalloproteinase‑9 by human blood monocytes upon adhering to carbamylated collagen. FEBS Lett 563:13–16PubMed Garnotel R, Sabbah N, Jaisson S, Gillery P (2004) Enhanced activation of and increased production of matrix metalloproteinase‑9 by human blood monocytes upon adhering to carbamylated collagen. FEBS Lett 563:13–16PubMed
64.
Zurück zum Zitat See F, Kompa A, Martin J, Lewis DA, Krum H (2005) Fibrosis as a therapeutic target post-myocardial infarction. Curr Pharm Des 11:477–487PubMed See F, Kompa A, Martin J, Lewis DA, Krum H (2005) Fibrosis as a therapeutic target post-myocardial infarction. Curr Pharm Des 11:477–487PubMed
65.
Zurück zum Zitat Fournet M, Bonte F, Glycation Damage DA (2018) A possible hub for major Pathophysiological disorders and aging. Aging Dis 9:880–900PubMedPubMedCentral Fournet M, Bonte F, Glycation Damage DA (2018) A possible hub for major Pathophysiological disorders and aging. Aging Dis 9:880–900PubMedPubMedCentral
66.
Zurück zum Zitat Gautieri A, Redaelli A, Buehler MJ, Vesentini S (2014) Age- and diabetes-related nonenzymatic crosslinks in collagen fibrils: candidate amino acids involved in advanced glycation end-products. Matrix Biol 34:89–95PubMed Gautieri A, Redaelli A, Buehler MJ, Vesentini S (2014) Age- and diabetes-related nonenzymatic crosslinks in collagen fibrils: candidate amino acids involved in advanced glycation end-products. Matrix Biol 34:89–95PubMed
67.
Zurück zum Zitat Sell DR, Monnier VM (2012) Molecular basis of arterial stiffening: role of glycation—a mini-review. Gerontology 58:227–237PubMed Sell DR, Monnier VM (2012) Molecular basis of arterial stiffening: role of glycation—a mini-review. Gerontology 58:227–237PubMed
68.
Zurück zum Zitat Kearney K, Tomlinson D, Smith K, Ajjan R (2017) Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol 16:34PubMedPubMedCentral Kearney K, Tomlinson D, Smith K, Ajjan R (2017) Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol 16:34PubMedPubMedCentral
69.
Zurück zum Zitat Genoud V, Quintana PG, Gionco S, Baldessari A, Quintana I (2018) Structural changes of fibrinogen molecule mediated by the N‑homocysteinylation reaction. J Thromb Thrombolysis 45:66–76PubMed Genoud V, Quintana PG, Gionco S, Baldessari A, Quintana I (2018) Structural changes of fibrinogen molecule mediated by the N‑homocysteinylation reaction. J Thromb Thrombolysis 45:66–76PubMed
70.
Zurück zum Zitat Svensson J, Bergman AC, Adamson U, Blomback M, Wallen H, Jorneskog G (2012) Acetylation and glycation of fibrinogen in vitro occur at specific lysine residues in a concentration dependent manner: a mass spectrometric and isotope labeling study. Biochem Biophys Res Commun 421:335–342PubMed Svensson J, Bergman AC, Adamson U, Blomback M, Wallen H, Jorneskog G (2012) Acetylation and glycation of fibrinogen in vitro occur at specific lysine residues in a concentration dependent manner: a mass spectrometric and isotope labeling study. Biochem Biophys Res Commun 421:335–342PubMed
Metadaten
Titel
Irreversible posttranslationale Modifikationen: potenzielle kardiovaskuläre Risikofaktoren
Ergebnisse & Erkenntnisse aus dem SFB/TRR219 „Molekulare Mechanismen kardiovaskulärer Erkrankungen bei chronischer Niereninsuffizienz“
verfasst von
Prof. Dr. Joachim Jankowski
Prof. Dr. Danilo Fliser
Publikationsdatum
25.02.2022
Verlag
Springer Medizin
Erschienen in
Die Kardiologie / Ausgabe 2/2022
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI
https://doi.org/10.1007/s12181-022-00534-8

Weitere Artikel der Ausgabe 2/2022

Die Kardiologie 2/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

TAVI bei kleinem Aortenklappenanulus: Es gibt noch ungeklärte Fragen

13.06.2024 TAVI Nachrichten

Zwischen selbstexpandierenden und ballonexpandierbaren TAVI-Klappen scheinen bezüglich der Klappenfunktion bei Aortenstenose und kleinem Aortenklappenanulus Unterschiede zu bestehen. Aber sind die überhaupt von klinischer Relevanz? Eine neue Studie liefert dazu Informationen.

Degenerierte Bioklappe: Ist Reoperation oder TAVI hier die bessere Option?

13.06.2024 TAVI Nachrichten

Im Fall eines Bioprothesen-Versagens nach Aortenklappenersatz kann ein notwendiger Revisionseingriff heute operativ oder kathetergestützt als Valve-in-Valve-TAVI vorgenommen werden. Eine Beobachtungsstudie lieferte neue Daten zum Vergleich beider Optionen.

Fortgeschrittenes Ovarial-Ca.: Unverdächtige Lymphknoten entfernen?

13.06.2024 ASCO 2024 Kongressbericht

Beim fortgeschrittenen Ovarialkarzinom und klinisch verdächtigen Lymphknoten in der Debulking-Op. ist die abdominale retroperitoneale Lymphadenektomie (RPL) Standard. Ohne verdächtige Lymphknoten ist der Nutzen fraglich.

Krillöl hilft nicht gegen Kniearthrose

13.06.2024 Arthrosen Nachrichten

Mit Krillöl zur Nahrungsergänzung lassen sich Schmerzen und Entzündungen bei Kniearthrose nicht stärker lindern als unter Placebo. Das hat eine kontrollierte Studie mit über 260 Betroffenen ergeben.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.